Minapharm’s Q1 consolidated profit up 8.8% YoY
Updated 5/31/2022 3:28:00 PM
Arab Finance: Minapharm Pharmaceuticals (Minapharm) (MIPH) reported an 8.85% year-on-year (YoY) increase in consolidated net profit attributable to the parent company for the first quarter (Q1) of 2022, according to the consolidated financial statement filed to the Egyptian Exchange (EGX) on May 31st.
Consolidated net profit excluding minority interest stood at EGP 130.50 million in Q1 2022, compared to EGP 119.88 million in Q1 2021.
Sales amounted to EGP 799.25 million in the first three months of 2022, up from EGP 772.69 million in Q1 2021.
Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.
